Influenza Diagnostics Market Synopsis

Influenza Diagnostics Market Size Was Valued at USD 1.23 Billion in 2023 and is Projected to Reach USD 1.95 Billion by 2032, Growing at a CAGR of 5.23% From 2024-2032.

Influenza diagnostics refers to the methods and techniques used to detect and identify the presence of influenza viruses in clinical samples collected from patients suspected of having influenza infection. These diagnostics include various laboratory tests such as rapid antigen tests, molecular tests (like PCR), and viral cultures. The goal of influenza diagnostics is to accurately and quickly identify the influenza virus strain present to guide patient management, treatment decisions, and public health interventions, especially during flu seasons or outbreaks.

• Influenza diagnostics are crucial tools in clinical settings for confirming influenza infection in patients with flu-like symptoms. They are used for disease surveillance, early detection and containment of the virus, and guiding antiviral treatment. Rapid diagnostic tests and molecular assays like PCR are commonly used for accurate diagnosis. In the event of a potential pandemic, these diagnostics help assess the severity of the outbreak, implement control measures, and guide vaccine distribution and treatment strategies. They also support infection control measures by identifying patients with influenza infection promptly, enabling isolation precautions, and protecting vulnerable patients and healthcare workers.
• Influenza diagnostics also guide vaccine strain selection, ensuring optimal effectiveness against circulating influenza viruses. They are also essential tools in influenza research, allowing for studies on virus epidemiology, transmission dynamics, pathogenesis, and vaccine development. Influenza, also known as the flu, is a highly contagious respiratory illness that causes annual outbreaks, especially during colder months. Accurate diagnosis of influenza infections is crucial for effective management, infection control measures, and timely treatment. Rapid diagnostic tests distinguish between influenza and other respiratory viruses, aiding healthcare providers in making accurate diagnoses and guiding treatment decisions.
• Influenza diagnostics are essential in public health surveillance, clinical management, workplace and school settings, travel and border control, and vaccine development. Early detection of cases allows for timely implementation of infection control measures, such as isolation and enhanced hygiene practices. Rapid testing at airports and border crossings helps identify individuals with influenza-like symptoms, reducing the risk of imported cases and localized outbreaks. Overall, influenza diagnostics play a vital role in public health surveillance, clinical management, and vaccine development.

Influenza Diagnostics Market Trend Analysis

Seasonal Influenza Outbreaks Drives the Need for Rapid and Accurate Diagnostic

• Rapid diagnosis of influenza is crucial for healthcare providers to promptly initiate appropriate treatment and management strategies for patients. Early administration of antiviral medications like Tamiflu is most effective, making timely diagnosis essential for optimal patient outcomes.
• Accurate diagnosis helps identify infected individuals quickly, enabling infection control measures to prevent further transmission, especially in settings like hospitals and schools. It also reduces unnecessary antibiotic use, as influenza is often mistaken for other respiratory infections, leading to unnecessary prescriptions. Rapid diagnostic tests also enable efficient resource allocation during influenza outbreaks, allowing better management of patient flow within healthcare facilities.
• Accurate diagnostic testing is essential for monitoring the spread of influenza within communities and identifying trends in disease activity. This information helps public health authorities implement targeted interventions, such as vaccination campaigns and public health messaging, to mitigate the impact of influenza outbreaks and protect public health.

Restraints

Molecular Diagnostic Tests often Require Specialized Equipment

• Molecular diagnostic tests for influenza require specialized equipment like PCR machines or nucleic acid amplification platforms, which can be expensive to purchase, install, and maintain. This can be a significant barrier for healthcare facilities, especially smaller clinics or laboratories with limited budgets.
• Operating and interpreting results from these tests require specialized technical expertise, which can be challenging in regions with limited access to trained personnel. Infrastructure requirements for these tests, such as dedicated lab space and reliable power sources, can be challenging to set up and maintain.
• Accessibility and availability of specialized equipment may be limited in rural or remote areas, low- and middle-income countries, and low- and middle-income countries. Regular maintenance and calibration of these equipment are also essential for ensuring test results' accuracy and reliability. Integrating these diagnostic technologies with existing systems can be complex and time-consuming.

Opportunity

Increasing Awareness of the Global Burden of Influenza

• The global burden of influenza is increasing, leading to a surge in demand for diagnostic tools to accurately detect infections. This is driven by the importance of early detection and containment of outbreaks to prevent the spread of the virus and reduce its impact on public health.
• Preventive measures, such as vaccination and early detection through diagnostic testing, are being encouraged, creating a market opportunity for influenza diagnostic manufacturers. Public health initiatives are prioritizing surveillance and control efforts, aiming to improve diagnostic capabilities and expand access to testing in healthcare settings.
• Technological advancements, such as molecular assays and rapid antigen tests, are enhancing the accuracy, speed, and accessibility of influenza diagnostics. This awareness extends beyond healthcare professionals to individuals, communities, and industries, creating opportunities for influenza diagnostic companies to expand their market reach and penetrate new segments.

Challenges

Access to Influenza Diagnostics may be Limited in Resource-Limited Settings

• Resource-limited settings often lack the necessary infrastructure, laboratory facilities, and equipment for influenza diagnostics, leading to financial constraints, personnel shortages, supply chain issues, geographical barriers, and prioritization of resources. These areas often lack access to basic laboratory equipment, such as PCR machines, antigen detection kits, and viral culture facilities. Financial constraints can hinder the procurement of diagnostic tests, while inadequately trained personnel can compromise the accuracy and reliability of testing.
• Supply chain disruptions can also limit access to diagnostic kits and reagents, causing delays or interruptions in testing services. Geographical barriers, such as limited transportation infrastructure and long distances to healthcare facilities, can further exacerbate underdiagnosis and inadequate surveillance. Prioritizing resources may result in gaps in disease monitoring and control efforts.

Influenza Diagnostics Market Segment Analysis:

Influenza Diagnostics Market Segmented based on virus type, method, and end-user.

By Virus Type, Seasonal Influenza segment is expected to dominate the market during the forecast period

• Seasonal influenza viruses, such as influenza A and B, cause frequent outbreaks during flu seasons, leading to a high demand for diagnostic tests to identify and monitor infections. These viruses pose significant public health challenges, causing severe illness, hospitalizations, and deaths, especially among vulnerable populations. Rapid and accurate diagnosis is crucial for timely interventions like antiviral treatment and vaccination campaigns.
• Healthcare providers rely on rapid diagnostic tests to distinguish between influenza and other respiratory infections with similar symptoms. Demand for influenza diagnostic tests typically peaks during flu seasons, with healthcare facilities, laboratories, and public health agencies stocking up on supplies. The market for influenza diagnostics is characterized by ongoing innovation and investment in new technologies, with the Virus Type, Seasonal Influenza segment dominating the market.

By Method, the Molecular Diagnostics segment held the largest share of 45.8% in 2023

• Molecular diagnostics, including PCR and NAATs, are highly sensitive and specific methods for detecting influenza viruses. They accurately identify viral RNA in patient samples, providing reliable results. These methods offer rapid detection, often within hours, allowing for prompt diagnosis and patient management. Molecular assays can also detect multiple influenza virus strains and subtypes simultaneously, enabling surveillance and differentiating between seasonal and potentially pandemic strains.
• Many molecular diagnostic platforms are automated, allowing for high-throughput testing in clinical laboratories. Technological advancements, such as point-of-care tests and portable PCR devices, have expanded the accessibility and utility of these methods for influenza diagnosis in various healthcare settings. Molecular methods have demonstrated superior performance in detecting influenza viruses, even in samples with low viral loads, which can occur early in the course of infection or in asymptomatic carriers.

Influenza Diagnostics Market Regional Insights:

North America is Expected to Dominate the Market Over the Forecast Period

• North America's advanced healthcare infrastructure, including hospitals, clinics, and diagnostic laboratories, facilitates widespread access to influenza diagnostic tests and timely diagnosis. The region's high healthcare expenditures, including one of the highest globally, support the adoption of innovative diagnostic technologies like molecular diagnostics and rapid antigen tests. North America's stringent regulatory standards ensure the quality, accuracy, and reliability of diagnostic tests, with manufacturers requiring FDA approvals.
• The high disease burden of influenza-related illnesses, particularly during the annual flu season, drives the demand for accurate and timely diagnostics. Public health agencies promote awareness campaigns and vaccination programs to prevent the virus's spread. North America is a hub for biomedical research and innovation, with collaborations between academic institutions, government agencies, and private sector companies driving advancements in influenza diagnostics, including novel assays, biomarkers, and point-of-care devices.

Influenza Diagnostics Market Top Key Players:

• Thermo Fisher Scientific Inc. (US)
• Abbott Laboratories (US)
• BD (Becton, Dickinson and Company) (US)
• Quidel Corporation (US)
• Luminex Corporation (US)
• Bio-Rad Laboratories, Inc. (US)
• Hologic, Inc. (US)
• Danaher Corporation (US)
• SA Scientific, Ltd. (US)
• Princeton BioMeditech Corporation (US)
• Gen-Probe Incorporated (US)
• BioFire Diagnostics, LLC (US)
• Meridian Bioscience, Inc. (US)
• Sekisui Diagnostics LLC (US)
• Cepheid (US)
• GenMark Diagnostics, Inc. (US)
• altona Diagnostics GmbH (Germany)
• QIAGEN N.V. (Germany)
• Siemens Healthineers AG (Germany)
• Randox Laboratories Ltd. (UK)
• Mologic Ltd. (United Kingdom) DiaSorin S.p.A. (Italy)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Roche Diagnostics (Switzerland)
• Sysmex Corporation (Japan), and other major players

Key Industry Developments in the Influenza Diagnostics Market:

• In July 2024, The U.S. Department of Health and Human Services (HHS), through the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR), will provide approximately $176 million to Moderna for development of an mRNA-based pandemic influenza vaccine.
• In June 2024, Roche announced that the U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for its cobas liat SARS-CoV-2, Influenza A/B & RSV nucleic acid test, an automated, multiplex, real-time polymerase chain reaction (RT-PCR) assay on the cobas® liat system. Producing results in just 20 minutes on a compact analyzer suitable for most healthcare settings, the test uses either a single nasopharyngeal or anterior nasal swab sample to confirm or rule out infection with SARS-CoV-2, influenza A virus, influenza B virus, and respiratory syncytial virus (RSV).

1. INTRODUCTION
   1. RESEARCH OBJECTIVES
   2. RESEARCH METHODOLOGY
   3. RESEARCH PROCESS
   4. SCOPE AND COVERAGE
      1. Market Definition
      2. Key Questions Answered
   5. MARKET SEGMENTATION
2. EXECUTIVE SUMMARY
3. MARKET OVERVIEW
4. GROWTH OPPORTUNITIES BY SEGMENT
5. MARKET LANDSCAPE
   1. PORTER’S FIVE FORCES ANALYSIS
      1. Bargaining Power Of Supplier
      2. Threat Of New Entrants
      3. Threat Of Substitutes
      4. Competitive Rivalry
      5. Bargaining Power Among Buyers
   2. INDUSTRY VALUE CHAIN ANALYSIS
   3. MARKET DYNAMICS
      1. Drivers
      2. Restraints
      3. Opportunities
      4. Challenges
   4. MARKET TREND ANALYSIS
   5. REGULATORY LANDSCAPE
   6. PESTLE ANALYSIS
   7. PRICE TREND ANALYSIS
   8. PATENT ANALYSIS
   9. TECHNOLOGY EVALUATION
   10. MARKET IMPACT OF THE RUSSIA-UKRAINE WAR
       1. Geopolitical Market Disruptions
       2. Supply Chain Disruptions
       3. Instability in Emerging Markets
   11. ECOSYSTEM
6. INFLUENZA DIAGNOSTICS MARKET BY VIRUS TYPE (2017-2032)
   1. INFLUENZA DIAGNOSTICS MARKET SNAPSHOT AND GROWTH ENGINE
   2. MARKET OVERVIEW
   3. SEASONAL INFLUENZA
      1. Introduction And Market Overview
      2. Historic And Forecasted Market Size in Value (2017 – 2032F)
      3. Historic And Forecasted Market Size in Volume (2017 – 2032F)
      4. Key Market Trends, Growth Factors And Opportunities
      5. Geographic Segmentation Analysis
   4. PANDEMIC INFLUENZA
   5. ZOONOTIC INFLUENZA
7. INFLUENZA DIAGNOSTICS MARKET BY METHOD (2017-2032)
   1. INFLUENZA DIAGNOSTICS MARKET SNAPSHOT AND GROWTH ENGINE
   2. MARKET OVERVIEW
   3. MOLECULAR DIAGNOSTICS
      1. Introduction And Market Overview
      2. Historic And Forecasted Market Size in Value (2017 – 2032F)
      3. Historic And Forecasted Market Size in Volume (2017 – 2032F)
      4. Key Market Trends, Growth Factors And Opportunities
      5. Geographic Segmentation Analysis
   4. IMMUNOASSAYS
   5. RIDT
8. INFLUENZA DIAGNOSTICS MARKET BY END USER (2017-2032)
   1. INFLUENZA DIAGNOSTICS MARKET SNAPSHOT AND GROWTH ENGINE
   2. MARKET OVERVIEW
   3. HOSPITALS AND CLINICS
      1. Introduction And Market Overview
      2. Historic And Forecasted Market Size in Value (2017 – 2032F)
      3. Historic And Forecasted Market Size in Volume (2017 – 2032F)
      4. Key Market Trends, Growth Factors And Opportunities
      5. Geographic Segmentation Analysis
   4. DIAGNOSTIC LABORATORIES
   5. RESEARCH INSTITUTES
9. COMPANY PROFILES AND COMPETITIVE ANALYSIS
   1. COMPETITIVE LANDSCAPE
      1. Competitive Positioning
      2. Influenza Diagnostics Market Share By Manufacturer (2023)
      3. Industry BCG Matrix
      4. Heat Map Analysis
      5. Mergers & Acquisitions
   2. THERMO FISHER SCIENTIFIC INC. (US)
      1. Company Overview
      2. Key Executives
      3. Company Snapshot
      4. Role of the Company in the Market
      5. Sustainability and Social Responsibility
      6. Operating Business Segments
      7. Product Portfolio
      8. Business Performance (Production Volume, Sales Volume, Sales Margin, Production Capacity, Capacity Utilization Rate)
      9. Key Strategic Moves And Recent Developments
      10. SWOT Analysis
   3. ABBOTT LABORATORIES (US)
   4. BD (BECTON, DICKINSON AND COMPANY) (US)
   5. QUIDEL CORPORATION (US)
   6. LUMINEX CORPORATION (US)
   7. BIO-RAD LABORATORIES, INC. (US)
   8. HOLOGIC, INC. (US)
   9. DANAHER CORPORATION (US)
   10. SA SCIENTIFIC, LTD. (US)
   11. PRINCETON BIOMEDITECH CORPORATION (US)
   12. GEN-PROBE INCORPORATED (US)
   13. BIOFIRE DIAGNOSTICS, LLC (US)
   14. MERIDIAN BIOSCIENCE, INC. (US)
   15. SEKISUI DIAGNOSTICS LLC (US)
   16. CEPHEID (US)
   17. GENMARK DIAGNOSTICS, INC. (US)
   18. ALTONA DIAGNOSTICS GMBH (GERMANY)
   19. QIAGEN N.V. (GERMANY)
   20. SIEMENS HEALTHINEERS AG (GERMANY)
   21. RANDOX LABORATORIES LTD. (UK)
   22. MOLOGIC LTD. (UNITED KINGDOM) DIASORIN S.P.A. (ITALY)
   23. F. HOFFMANN-LA ROCHE LTD. (SWITZERLAND)
   24. ROCHE DIAGNOSTICS (SWITZERLAND)
   25. SYSMEX CORPORATION (JAPAN)
10. GLOBAL INFLUENZA DIAGNOSTICS MARKET BY REGION
    1. OVERVIEW
    2. NORTH AMERICA
       1. Key Market Trends, Growth Factors And Opportunities
       2. Key Manufacturers
       3. Historic And Forecasted Market Size By Virus Type
       4. Historic And Forecasted Market Size By Method
       5. Historic And Forecasted Market Size By End User
       6. Historic And Forecasted Market Size By Country
          1. USA
          2. Canada
          3. Mexico
    3. EASTERN EUROPE
       1. Key Market Trends, Growth Factors And Opportunities
       2. Key Manufacturers
       3. Historic And Forecasted Market Size By Segments
       4. Historic And Forecasted Market Size By Country
          1. Russia
          2. Bulgaria
          3. The Czech Republic
          4. Hungary
          5. Poland
          6. Romania
          7. Rest Of Eastern Europe
    4. WESTERN EUROPE
       1. Key Market Trends, Growth Factors And Opportunities
       2. Key Manufacturers
       3. Historic And Forecasted Market Size By Segments
       4. Historic And Forecasted Market Size By Country
          1. Germany
          2. United Kingdom
          3. France
          4. The Netherlands
          5. Italy
          6. Spain
          7. Rest Of Western Europe
    5. ASIA PACIFIC
       1. Key Market Trends, Growth Factors And Opportunities
       2. Key Manufacturers
       3. Historic And Forecasted Market Size By Segments
       4. Historic And Forecasted Market Size By Country
          1. China
          2. India
          3. Japan
          4. South Korea
          5. Malaysia
          6. Thailand
          7. Vietnam
          8. The Philippines
          9. Australia
          10. New-Zealand
          11. Rest Of APAC
    6. MIDDLE EAST & AFRICA
       1. Key Market Trends, Growth Factors And Opportunities
       2. Key Manufacturers
       3. Historic And Forecasted Market Size By Segments
       4. Historic And Forecasted Market Size By Country
          1. Turkey
          2. Bahrain
          3. Kuwait
          4. Saudi Arabia
          5. Qatar
          6. UAE
          7. Israel
          8. South Africa
    7. SOUTH AMERICA
       1. Key Market Trends, Growth Factors And Opportunities
       2. Key Manufacturers
       3. Historic And Forecasted Market Size By Segments
       4. Historic And Forecasted Market Size By Country
          1. Brazil
          2. Argentina
          3. Rest of South America
11. INVESTMENT ANALYSIS
12. ANALYST VIEWPOINT AND CONCLUSION
    1. Recommendations and Concluding Analysis
    2. Potential Market Strategies

LIST OF TABLES

TABLE 001. EXECUTIVE SUMMARY
TABLE 002. INFLUENZA DIAGNOSTICS MARKET BARGAINING POWER OF SUPPLIERS
TABLE 003. INFLUENZA DIAGNOSTICS MARKET BARGAINING POWER OF CUSTOMERS
TABLE 004. INFLUENZA DIAGNOSTICS MARKET COMPETITIVE RIVALRY
TABLE 005. INFLUENZA DIAGNOSTICS MARKET THREAT OF NEW ENTRANTS
TABLE 006. INFLUENZA DIAGNOSTICS MARKET THREAT OF SUBSTITUTES
TABLE 007. INFLUENZA DIAGNOSTICS MARKET BY TYPE
TABLE 008. TRADITIONAL {RAPID INFLUENZA DETECTION TESTS MARKET OVERVIEW (2016-2028)
TABLE 009. VIRAL CULTURE MARKET OVERVIEW (2016-2028)
TABLE 010. IMMUNOASSAY KITS MARKET OVERVIEW (2016-2028)
TABLE 011. IMMUNOFLUORESCENCE ASSAYS MARKET OVERVIEW (2016-2028)
TABLE 012. SEROLOGICAL TESTING} MARKET OVERVIEW (2016-2028)
TABLE 013. MOLECULAR {RAPID MOLECULAR ASSAYS MARKET OVERVIEW (2016-2028)
TABLE 014. REVERSE TRANSCRIPTION-POLYMERASE CHAIN REACTION {RT-PCR} MARKET OVERVIEW (2016-2028)
TABLE 015. NUCLEIC ACID AMPLIFICATION MARKET OVERVIEW (2016-2028)
TABLE 016. INFLUENZA DIAGNOSTICS MARKET BY END USERS
TABLE 017. CLINICAL LABORATORIES MARKET OVERVIEW (2016-2028)
TABLE 018. HOSPITALS MARKET OVERVIEW (2016-2028)
TABLE 019. RESEARCH & ACADEMIC INSTITUTES MARKET OVERVIEW (2016-2028)
TABLE 020. DIAGNOSTIC LABORATORIES MARKET OVERVIEW (2016-2028)
TABLE 021. NORTH AMERICA INFLUENZA DIAGNOSTICS MARKET, BY TYPE (2016-2028)
TABLE 022. NORTH AMERICA INFLUENZA DIAGNOSTICS MARKET, BY END USERS (2016-2028)
TABLE 023. N INFLUENZA DIAGNOSTICS MARKET, BY COUNTRY (2016-2028)
TABLE 024. EUROPE INFLUENZA DIAGNOSTICS MARKET, BY TYPE (2016-2028)
TABLE 025. EUROPE INFLUENZA DIAGNOSTICS MARKET, BY END USERS (2016-2028)
TABLE 026. INFLUENZA DIAGNOSTICS MARKET, BY COUNTRY (2016-2028)
TABLE 027. ASIA PACIFIC INFLUENZA DIAGNOSTICS MARKET, BY TYPE (2016-2028)
TABLE 028. ASIA PACIFIC INFLUENZA DIAGNOSTICS MARKET, BY END USERS (2016-2028)
TABLE 029. INFLUENZA DIAGNOSTICS MARKET, BY COUNTRY (2016-2028)
TABLE 030. MIDDLE EAST & AFRICA INFLUENZA DIAGNOSTICS MARKET, BY TYPE (2016-2028)
TABLE 031. MIDDLE EAST & AFRICA INFLUENZA DIAGNOSTICS MARKET, BY END USERS (2016-2028)
TABLE 032. INFLUENZA DIAGNOSTICS MARKET, BY COUNTRY (2016-2028)
TABLE 033. SOUTH AMERICA INFLUENZA DIAGNOSTICS MARKET, BY TYPE (2016-2028)
TABLE 034. SOUTH AMERICA INFLUENZA DIAGNOSTICS MARKET, BY END USERS (2016-2028)
TABLE 035. INFLUENZA DIAGNOSTICS MARKET, BY COUNTRY (2016-2028)
TABLE 036. DANAHER CORPORATION: SNAPSHOT
TABLE 037. DANAHER CORPORATION: BUSINESS PERFORMANCE
TABLE 038. DANAHER CORPORATION: PRODUCT PORTFOLIO
TABLE 039. DANAHER CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 039. SIEMENS HEALTHINEERS: SNAPSHOT
TABLE 040. SIEMENS HEALTHINEERS: BUSINESS PERFORMANCE
TABLE 041. SIEMENS HEALTHINEERS: PRODUCT PORTFOLIO
TABLE 042. SIEMENS HEALTHINEERS: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 042. THERMO FISHER SCIENTIFIC INC.: SNAPSHOT
TABLE 043. THERMO FISHER SCIENTIFIC INC.: BUSINESS PERFORMANCE
TABLE 044. THERMO FISHER SCIENTIFIC INC.: PRODUCT PORTFOLIO
TABLE 045. THERMO FISHER SCIENTIFIC INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 045. F. HOFFMANN-LA ROCHE AG: SNAPSHOT
TABLE 046. F. HOFFMANN-LA ROCHE AG: BUSINESS PERFORMANCE
TABLE 047. F. HOFFMANN-LA ROCHE AG: PRODUCT PORTFOLIO
TABLE 048. F. HOFFMANN-LA ROCHE AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 048. ABBOTT LABORATORIES INC.: SNAPSHOT
TABLE 049. ABBOTT LABORATORIES INC.: BUSINESS PERFORMANCE
TABLE 050. ABBOTT LABORATORIES INC.: PRODUCT PORTFOLIO
TABLE 051. ABBOTT LABORATORIES INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 051. HOLOGIC INC.: SNAPSHOT
TABLE 052. HOLOGIC INC.: BUSINESS PERFORMANCE
TABLE 053. HOLOGIC INC.: PRODUCT PORTFOLIO
TABLE 054. HOLOGIC INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 054. BIOMÉRIEUX SA: SNAPSHOT
TABLE 055. BIOMÉRIEUX SA: BUSINESS PERFORMANCE
TABLE 056. BIOMÉRIEUX SA: PRODUCT PORTFOLIO
TABLE 057. BIOMÉRIEUX SA: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 057. QUIDEL CORPORATION: SNAPSHOT
TABLE 058. QUIDEL CORPORATION: BUSINESS PERFORMANCE
TABLE 059. QUIDEL CORPORATION: PRODUCT PORTFOLIO
TABLE 060. QUIDEL CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 060. BECTON: SNAPSHOT
TABLE 061. BECTON: BUSINESS PERFORMANCE
TABLE 062. BECTON: PRODUCT PORTFOLIO
TABLE 063. BECTON: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 063. DICKINSON AND COMPANY: SNAPSHOT
TABLE 064. DICKINSON AND COMPANY: BUSINESS PERFORMANCE
TABLE 065. DICKINSON AND COMPANY: PRODUCT PORTFOLIO
TABLE 066. DICKINSON AND COMPANY: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 066. MERIDIAN BIOSCIENCE: SNAPSHOT
TABLE 067. MERIDIAN BIOSCIENCE: BUSINESS PERFORMANCE
TABLE 068. MERIDIAN BIOSCIENCE: PRODUCT PORTFOLIO
TABLE 069. MERIDIAN BIOSCIENCE: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 069. GENMARK DIAGNOSTICS INC.: SNAPSHOT
TABLE 070. GENMARK DIAGNOSTICS INC.: BUSINESS PERFORMANCE
TABLE 071. GENMARK DIAGNOSTICS INC.: PRODUCT PORTFOLIO
TABLE 072. GENMARK DIAGNOSTICS INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 072. LUMINEX CORPORATION: SNAPSHOT
TABLE 073. LUMINEX CORPORATION: BUSINESS PERFORMANCE
TABLE 074. LUMINEX CORPORATION: PRODUCT PORTFOLIO
TABLE 075. LUMINEX CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 075. TECAN TRADING AG: SNAPSHOT
TABLE 076. TECAN TRADING AG: BUSINESS PERFORMANCE
TABLE 077. TECAN TRADING AG: PRODUCT PORTFOLIO
TABLE 078. TECAN TRADING AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 078. DIASORIN SA: SNAPSHOT
TABLE 079. DIASORIN SA: BUSINESS PERFORMANCE
TABLE 080. DIASORIN SA: PRODUCT PORTFOLIO
TABLE 081. DIASORIN SA: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 081. ALTONA DIAGNOSTICS GMBH: SNAPSHOT
TABLE 082. ALTONA DIAGNOSTICS GMBH: BUSINESS PERFORMANCE
TABLE 083. ALTONA DIAGNOSTICS GMBH: PRODUCT PORTFOLIO
TABLE 084. ALTONA DIAGNOSTICS GMBH: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 084. SEKISUI DIAGNOSTICS: SNAPSHOT
TABLE 085. SEKISUI DIAGNOSTICS: BUSINESS PERFORMANCE
TABLE 086. SEKISUI DIAGNOSTICS: PRODUCT PORTFOLIO
TABLE 087. SEKISUI DIAGNOSTICS: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 087. SA SCIENTIFIC LTD.: SNAPSHOT
TABLE 088. SA SCIENTIFIC LTD.: BUSINESS PERFORMANCE
TABLE 089. SA SCIENTIFIC LTD.: PRODUCT PORTFOLIO
TABLE 090. SA SCIENTIFIC LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 090. CORIS BIOCONCEPT SPRL: SNAPSHOT
TABLE 091. CORIS BIOCONCEPT SPRL: BUSINESS PERFORMANCE
TABLE 092. CORIS BIOCONCEPT SPRL: PRODUCT PORTFOLIO
TABLE 093. CORIS BIOCONCEPT SPRL: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 093. ELITECH GROUP: SNAPSHOT
TABLE 094. ELITECH GROUP: BUSINESS PERFORMANCE
TABLE 095. ELITECH GROUP: PRODUCT PORTFOLIO
TABLE 096. ELITECH GROUP: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 096. MAST GROUP LTD.: SNAPSHOT
TABLE 097. MAST GROUP LTD.: BUSINESS PERFORMANCE
TABLE 098. MAST GROUP LTD.: PRODUCT PORTFOLIO
TABLE 099. MAST GROUP LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 099. GENOME DIAGNOSTICS PVT. LTD.: SNAPSHOT
TABLE 100. GENOME DIAGNOSTICS PVT. LTD.: BUSINESS PERFORMANCE
TABLE 101. GENOME DIAGNOSTICS PVT. LTD.: PRODUCT PORTFOLIO
TABLE 102. GENOME DIAGNOSTICS PVT. LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 102. GERMAINE LABORATORIES INC.: SNAPSHOT
TABLE 103. GERMAINE LABORATORIES INC.: BUSINESS PERFORMANCE
TABLE 104. GERMAINE LABORATORIES INC.: PRODUCT PORTFOLIO
TABLE 105. GERMAINE LABORATORIES INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 105. RESPONSE BIOMEDICAL CORP.: SNAPSHOT
TABLE 106. RESPONSE BIOMEDICAL CORP.: BUSINESS PERFORMANCE
TABLE 107. RESPONSE BIOMEDICAL CORP.: PRODUCT PORTFOLIO
TABLE 108. RESPONSE BIOMEDICAL CORP.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 108. TAUNS LABORATORIESINC.: SNAPSHOT
TABLE 109. TAUNS LABORATORIESINC.: BUSINESS PERFORMANCE
TABLE 110. TAUNS LABORATORIESINC.: PRODUCT PORTFOLIO
TABLE 111. TAUNS LABORATORIESINC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 111. 3B BLACKBIO BIOTECH INDIA LTD.: SNAPSHOT
TABLE 112. 3B BLACKBIO BIOTECH INDIA LTD.: BUSINESS PERFORMANCE
TABLE 113. 3B BLACKBIO BIOTECH INDIA LTD.: PRODUCT PORTFOLIO
TABLE 114. 3B BLACKBIO BIOTECH INDIA LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 114. OTHER MAJOR PLAYERS: SNAPSHOT
TABLE 115. OTHER MAJOR PLAYERS: BUSINESS PERFORMANCE
TABLE 116. OTHER MAJOR PLAYERS: PRODUCT PORTFOLIO
TABLE 117. OTHER MAJOR PLAYERS: KEY STRATEGIC MOVES AND DEVELOPMENTS

LIST OF FIGURES

FIGURE 001. YEARS CONSIDERED FOR ANALYSIS
FIGURE 002. SCOPE OF THE STUDY
FIGURE 003. INFLUENZA DIAGNOSTICS MARKET OVERVIEW BY REGIONS
FIGURE 004. PORTER'S FIVE FORCES ANALYSIS
FIGURE 005. BARGAINING POWER OF SUPPLIERS
FIGURE 006. COMPETITIVE RIVALRYFIGURE 007. THREAT OF NEW ENTRANTS
FIGURE 008. THREAT OF SUBSTITUTES
FIGURE 009. VALUE CHAIN ANALYSIS
FIGURE 010. PESTLE ANALYSIS
FIGURE 011. INFLUENZA DIAGNOSTICS MARKET OVERVIEW BY TYPE
FIGURE 012. TRADITIONAL {RAPID INFLUENZA DETECTION TESTS MARKET OVERVIEW (2016-2028)
FIGURE 013. VIRAL CULTURE MARKET OVERVIEW (2016-2028)
FIGURE 014. IMMUNOASSAY KITS MARKET OVERVIEW (2016-2028)
FIGURE 015. IMMUNOFLUORESCENCE ASSAYS MARKET OVERVIEW (2016-2028)
FIGURE 016. SEROLOGICAL TESTING} MARKET OVERVIEW (2016-2028)
FIGURE 017. MOLECULAR {RAPID MOLECULAR ASSAYS MARKET OVERVIEW (2016-2028)
FIGURE 018. REVERSE TRANSCRIPTION-POLYMERASE CHAIN REACTION {RT-PCR} MARKET OVERVIEW (2016-2028)
FIGURE 019. NUCLEIC ACID AMPLIFICATION MARKET OVERVIEW (2016-2028)
FIGURE 020. INFLUENZA DIAGNOSTICS MARKET OVERVIEW BY END USERS
FIGURE 021. CLINICAL LABORATORIES MARKET OVERVIEW (2016-2028)
FIGURE 022. HOSPITALS MARKET OVERVIEW (2016-2028)
FIGURE 023. RESEARCH & ACADEMIC INSTITUTES MARKET OVERVIEW (2016-2028)
FIGURE 024. DIAGNOSTIC LABORATORIES MARKET OVERVIEW (2016-2028)
FIGURE 025. NORTH AMERICA INFLUENZA DIAGNOSTICS MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 026. EUROPE INFLUENZA DIAGNOSTICS MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 027. ASIA PACIFIC INFLUENZA DIAGNOSTICS MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 028. MIDDLE EAST & AFRICA INFLUENZA DIAGNOSTICS MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 029. SOUTH AMERICA INFLUENZA DIAGNOSTICS MARKET OVERVIEW BY COUNTRY (2016-2028)